Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Notice of Effectiveness · EFFECT

Werewolf Therapeutics, Inc.

HOWLNASDAQEQUITYCurrent

Notice of Effectiveness

Filed Nov 12, 2026Accepted Nov 13, 2026, 12:15 AM ESTFiling CIK 1785530Accession 9999999995-26-003522
Share

Structured filing — EFFECT

primary_doc.xml

Open full document ↗

Notice details

Submission type
EFFECT
Act
33

Effectiveness

Effective date
2026-11-12
Effective time (as filed)
16:30:00
Form
S-4

Registrant 1

Registrant
Werewolf Therapeutics, Inc.
Registrant CIK
0001785530
File number
333-299079

Company context

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company has designed conditionally activated INDUKINETM molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. To learn more visit www.werewolftx.com.

Current securities

Recent company filings

  1. 10-Q filingNov 13, 2026
  2. 424B3 filingNov 12, 2026
  3. S-4/A filingNov 10, 2026
  4. 425 filingNov 10, 2026
  5. Regulation FD DisclosureNov 9, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.